As of 2024-12-13, the EV/EBITDA ratio of Sangamo Therapeutics Inc (SGMO) is -2.19. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGMO's latest enterprise value is 359.32 mil USD. SGMO's TTM EBITDA according to its financial statements is -164.15 mil USD. Dividing these 2 quantities gives us the above SGMO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.0x | 16.0x |
| Forward P/E multiples | 15.4x - 21.2x | 15.7x |
| Fair Price | (11.93) - (13.15) | (12.28) |
| Upside | -724.5% - -788.7% | -743.0% |
| Date | EV/EBITDA |
| 2024-12-12 | -2.19 |
| 2024-12-11 | -2.23 |
| 2024-12-10 | -2.24 |
| 2024-12-09 | -2.30 |
| 2024-12-06 | -2.32 |
| 2024-12-05 | -2.27 |
| 2024-12-04 | -2.23 |
| 2024-12-03 | -2.49 |
| 2024-12-02 | -2.76 |
| 2024-11-29 | -2.63 |
| 2024-11-27 | -2.68 |
| 2024-11-26 | -2.48 |
| 2024-11-25 | -2.23 |
| 2024-11-22 | -2.15 |
| 2024-11-21 | -2.25 |
| 2024-11-20 | -2.24 |
| 2024-11-19 | -2.25 |
| 2024-11-18 | -2.18 |
| 2024-11-15 | -2.37 |
| 2024-11-14 | -2.49 |
| 2024-11-13 | -2.86 |
| 2024-11-12 | -3.21 |
| 2024-11-11 | -3.19 |
| 2024-11-08 | -3.41 |
| 2024-11-07 | -3.33 |
| 2024-11-06 | -2.90 |
| 2024-11-05 | -2.51 |
| 2024-11-04 | -1.97 |
| 2024-11-01 | -2.15 |
| 2024-10-31 | -1.92 |
| 2024-10-30 | -2.29 |
| 2024-10-29 | -2.30 |
| 2024-10-28 | -2.35 |
| 2024-10-25 | -1.67 |
| 2024-10-24 | -1.66 |
| 2024-10-23 | -1.72 |
| 2024-10-22 | -1.30 |
| 2024-10-21 | -0.92 |
| 2024-10-18 | -0.93 |
| 2024-10-17 | -0.95 |
| 2024-10-16 | -1.02 |
| 2024-10-15 | -1.00 |
| 2024-10-14 | -0.94 |
| 2024-10-11 | -0.83 |
| 2024-10-10 | -0.81 |
| 2024-10-09 | -0.77 |
| 2024-10-08 | -0.79 |
| 2024-10-07 | -0.78 |
| 2024-10-04 | -0.75 |
| 2024-10-03 | -0.77 |